Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tislelizumab, Afatinib, and Chemotherapy in Head and Neck Cancer
NCT05516589Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, afatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by West China Hospital of Sichuan University. Started Sep 2022; status: completed.
02
Drugs
tislelizumabafatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05516589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516589.